GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioArctic AB (OTCPK:BRCTF) » Definitions » Cash Ratio

BRCTF (BioArctic AB) Cash Ratio : 5.10 (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is BioArctic AB Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. BioArctic AB's Cash Ratio for the quarter that ended in Sep. 2024 was 5.10.

BioArctic AB has a Cash Ratio of 5.10. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for BioArctic AB's Cash Ratio or its related term are showing as below:

BRCTF' s Cash Ratio Range Over the Past 10 Years
Min: 1.08   Med: 6.84   Max: 16.07
Current: 5.1

During the past 9 years, BioArctic AB's highest Cash Ratio was 16.07. The lowest was 1.08. And the median was 6.84.

BRCTF's Cash Ratio is ranked better than
66.01% of 1474 companies
in the Biotechnology industry
Industry Median: 2.675 vs BRCTF: 5.10

BioArctic AB Cash Ratio Historical Data

The historical data trend for BioArctic AB's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioArctic AB Cash Ratio Chart

BioArctic AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only 7.46 9.20 8.38 11.36 8.89

BioArctic AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.21 8.89 3.81 3.41 5.10

Competitive Comparison of BioArctic AB's Cash Ratio

For the Biotechnology subindustry, BioArctic AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioArctic AB's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioArctic AB's Cash Ratio distribution charts can be found below:

* The bar in red indicates where BioArctic AB's Cash Ratio falls into.



BioArctic AB Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

BioArctic AB's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=108.365/12.183
=8.89

BioArctic AB's Cash Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash Ratio (Q: Sep. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=59.094/11.586
=5.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioArctic AB  (OTCPK:BRCTF) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


BioArctic AB Cash Ratio Related Terms

Thank you for viewing the detailed overview of BioArctic AB's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioArctic AB Business Description

Traded in Other Exchanges
Address
Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. In addition, the group is also focused on the development of a treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury. Geographically, it derives a majority of its revenue from Asia.

BioArctic AB Headlines

From GuruFocus

Full Year 2020 BioArctic AB Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q1 2022 BioArctic AB Earnings Call Transcript

By GuruFocus Research 02-13-2024

BioArctic winner of the Allbright Award 2020

By PRNewswire PRNewswire 10-15-2020

Q3 2022 BioArctic AB Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q2 2019 BioArctic AB Earnings Call Transcript

By GuruFocus Research 02-13-2024

Eisai increases the number of participants in Clarity AD study

By PRNewswire PRNewswire 02-03-2021

Q1 2019 BioArctic AB Earnings Call Transcript

By GuruFocus Research 02-13-2024

Nine Months 2020 BioArctic AB Earnings Call Transcript

By GuruFocus Research 02-13-2024